Press Releases June 22, 2026 06:41 AM

DHT Holdings, Inc. announces the results of the 2026 annual meeting of shareholders

DHT Holdings announces 2026 Annual Meeting outcomes including director election and auditor ratification

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
DHT

DHT Holdings, Inc. held its 2026 Annual Meeting where shareholders elected Jeremy Kramer as a Class I director and ratified Ernst & Young AS as the independent registered public accounting firm for the fiscal year ending 2026. Shareholders representing over 63% of shares participated in the meeting.

DHT Holdings, Inc. announces the results of the 2026 annual meeting of shareholders
DHT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Jeremy Kramer was elected to the Board of Directors for a three-year term.
  • Ernst & Young AS was ratified as the independent registered public accounting firm for 2026.
  • Shareholders representing approximately 63% of common shares participated in the meeting.

HAMILTON, BERMUDA, June 22, 2026 – DHT Holdings, Inc. (NYSE:DHT) (“DHT”) announces the results of its 2026 Annual Meeting of Shareholders (the “Annual Meeting”), held on Thursday, June 18, 2026. Shareholders holding an aggregate of 101,497,532 common shares of DHT were present or represented by proxy at the Annual Meeting, representing approximately 63.03% of the issued and outstanding common shares of DHT as of the close of business on April 23, 2026, the record date for the meeting.

At the Annual Meeting, the shareholders voted (1) to elect Jeremy Kramer to DHT’s Board of Directors as a Class I director for a term of three years, and (2) to ratify the selection of Ernst & Young AS as DHT’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

The detailed voting results were as follows:

1)   Election of Director


Shareholders elected Jeremy Kramer to DHT’s Board of Directors as a Class I director for a term of three years. The votes cast were 70,975,622 in favor (representing 69.93% of the total votes cast), 26,847,647 withheld, and 3,674,263 broker non-votes.

2)   Ratification of Independent Registered Public Accounting Firm


Shareholders ratified the selection of Ernst & Young AS as DHT’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were 101,354,521 in favor (representing 99.86% of the total votes cast), 80,357 against, and 62,654 votes abstentions.

About DHT Holdings, Inc.
DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles; our fleet employment with a combination of market exposure and fixed income contracts; our disciplined capital allocation strategy through cash dividends, investments in vessels, debt prepayments and share buybacks; and our transparent corporate structure maintaining a high level of integrity and corporate governance. For further information please visit www.dhtankers.com.

Contact:
Laila C. Halvorsen, CFO
Phone: +1 441 295 1422 and +47 984 39 935
E-mail: [email protected]


Risks

  • Significant withheld votes and broker non-votes in the director election indicate possible shareholder concerns or indecision.
  • Dependence on global crude oil tanker market conditions presents cyclical business risks impacting revenue.
  • Maintaining prudent capital structure amid volatile shipping and energy markets requires careful management to sustain business stability.

More from Press Releases

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial Jun 22, 2026 Outdoor Holding Company Reports Fourth Quarter and Fiscal Year 2026 Financial Results Jun 22, 2026 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts Jun 22, 2026 LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection Jun 22, 2026 Westport Announces US$10 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Jun 22, 2026